Price T Rowe Associates Inc Summit Therapeutics Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 6,557,927 shares of SMMT stock, worth $145 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
6,557,927
Previous 5,439,657
20.56%
Holding current value
$145 Million
Previous $119 Million
1.79%
% of portfolio
0.01%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding SMMT
# of Institutions
232Shares Held
83.1MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$540 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$258 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$175 Million0.0% of portfolio
-
State Street Corp Boston, MA5.6MShares$124 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.2MShares$70.8 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.45B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...